An observational study in Migraine and Headache Disorders, sponsored by Region Stockholm. Not yet recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Region Stockholm · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Migraine Disorders with a site in Sweden — 6 open to participants now, 9 under way, 3 of them phase 3. Migraine Disorders · Sweden.
Among the 38 studies in Migraine Disorders with a site in Sweden, this one is the only one that started in 2027, is one of 5 observational ones, and was the 38th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →6 of the 38 studies in Migraine Disorders with a site in Sweden are open now. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden
Ages 18–65
AbbVie · Sites in Sweden, United States, Belgium and 13 more countries
Ages 6–17
Pfizer · Sites in Sweden, United States, Canada and 6 more countries
Ages 6–17
AbbVie · Sites in Sweden, United States, Belgium and 13 more countries
Ages 6–17
Vastra Gotaland Region · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 13 · Phase 4 5
First in 1999; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 137 across 331 observational studies indexed under Migraine Disorders.
Median enrollment 448 across the 32 interventional studies, 641 across the 5 observational. Of the 28 that completed or were terminated, 19 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 38 have an industry lead sponsor. The 10 most frequent:
Region Stockholm is the lead sponsor of 122 studies on the registry; 70 are open to participants now.
Region Stockholm has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Migraine Disorders with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07279623Abilion Medical Systems ABIntra-Nasal Mechanical Stimulation (INMEST) as a Potential Preventative Treatment for Migraine | 2026-11 |
| NCT07292090Karolinska InstitutetYogabased Movements for Primary Headaches (Migraine and/or Cluster Headache) - YOURHEAD - a Pilot Study | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 38 studies in Migraine Disorders with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to:
Develop and validate a Headache Evaluation to support Anamnesis and Diagnostics (HEAD)-instrument for use to improve consultation time and support thorough headache anamnesis and history taking at the first specialist headache consultation (test study) addressing a well-documented gap in current care and directly operationalising the H@H principle of extending structured clinical support into the patient's pathway before hospital contact.
Improve headache care by providing a more digital longitudinal support from first visit and during follow up of chronic severe headache disorders, with primary focus on migraines, with better and more timely assessment of treatment response and disease burden to promote appropriate change of care regime (implementation study).
Testing phase of the study developing the HEAD instrument: Patients attending headache clinics at the three sites (300 patients in total) will be included, 150 will be recruited for the development phase and 150 for the validation phase.
Implementation phase: Patients (300 patients in total - three recruiting sites) with new referal to the clinic will be included in the digital pathway including the HEAD instrument and digital follow-up questionnaires and headache diary. Depending on results for the testing phase this phase will be adjusted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients seeking medical help at specialist care for headache or facial pain disorder, largest group of patients will be patients with migraine diagnosis
Diagnostic Test: HEAD instrument
Using patients own input prior to first visit at a specialist center (by filling in a advanced on-line questionnaire) we intend to support the clinical visit so that the clinican will recieve an anamnestic summarise of the patients history by using a by project developed AI module which will also be validated in this study and integrated in a digital pathway in treating severe migraine and headache patients in specialised care enviroment.
Headache diagnosis
Provide a high agreement between the HEAD instruments output of diagnosis and treatment suggestions compared to reference standard (independent blinded medical record review and diagnosis and treatment standards)?
Time frame: 1,5 year
Headache anamnesis
Produce a good summary of patients' anamnesis according to physicians?
Time frame: 1,5 year
Headache severity
Detect headache severity and thereby support earlier identification of patients at risk of migraine chronification?
Time frame: 1,5 Year
Userfriendliness
Is the developed questionnaire and HEAD instrument user-friendly for physicians and patients based on a 7-point Likert scale answers?
Time frame: 1,5 year
Agreement with set diagnosis
To what extent does the HEAD instrument show agreement with set diagnosis from clinicians?
Time frame: 1,5 year
Omission rate of HEAD instrument
What is the omission rate or citation rate of the HEAD instrument (the diagnosis does not appear by the top three diagnosis suggestions from the HEAD instrument or appears in at least any of the three top three diagnosis suggestions)?
Time frame: 1,5 year
Time efficiency
Does the HEAD instrument and digital follow up improve the use of consultation time and with higher quality for the physicians and patients?
Time frame: 1,5 year
Implementation study
How well does a more digital pathway for migaine diagnosis, support and follow up improve the overall care for headache patients?
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2030, 36 months later.
Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 36 months is above that.
Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 13 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.